This trial is active, not recruiting.

Condition healthy
Treatment isoquercetin or quercetin
Phase early phase 1
Sponsor Beth Israel Deaconess Medical Center
Start date May 2012
End date March 2017
Trial size 40 participants
Trial identifier NCT01722669, 2012P000022


The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model parallel assignment
Primary purpose basic science
Masking no masking
Single dose of quercetin with or without ascorbic acid
isoquercetin or quercetin
Single dose PK/PD study
(Active Comparator)
Single dose of isoquercetin with or without ascorbic acid
isoquercetin or quercetin
Single dose PK/PD study

Primary Outcomes

Pharmacokinetics profile
time frame: 24 hours

Secondary Outcomes

pharmacokinetic inhibition of PDI
time frame: 24 hours
Thrombin generation
time frame: 4 hours

Eligibility Criteria

All participants from 18 years up to 80 years old.

Inclusion Criteria - Subject is willing to participate and provide informed consent - Subject is considered reliable and capable of adhering to the protocol per the judgment of the Investigator - Subjects in group D must exhibit good organ reserves (within prior 4 weeks) defined as: 1. Estimated GFR >35 (formula), 2. Platelet count >65 K/uL, 3. Hemoglobin >10.5 grams/dL 4. Total bilirubin <2.0 mg/dL - Minimum age 18 years old - Body mass index (BMI) between 18 and 35 kg/m2 - For cohort D (antiphospholipid antibodies) a. Subjects in group D must have at least one positive antiphospholipid antibody within the last 8 weeks and/or previous confirmed antibodies (2 or more occasions at least 12 weeks apart) : i. Positive lupus anticoagulant ii. anticardiolipin antibody IgM or IgG (>40U GPL) iii. anti-β2 Glycoprotein1 antibody titer (>35 units) Exclusion Criteria - Pregnant. If female of child-bearing age, negative urinary pregnancy test prior to dosing of quercetin or isoquercetin - No history of malabsorptive gastrointestinal disorder - Currently taking aspirin, NSAIDS, warfarin, low-molecular weight heparin or other anticoagulants (such as direct thrombin inhibitors or factor X inhibitors) a. Note: Study subjects taking aspirin or NSAIDS, if treating physician concurs, are permitted to enroll if plan to hold for aspirin 10 days or NSAIDS 24 hours prior to dosing of quercetin/isoquercetin - Prescribed niacin for hyperlipidemia - Known HIV - History of sensitivity or intolerance to flavonoids, niacin or ascorbic acid - May not have uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia

Additional Information

Official title Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies
Principal investigator Jeffrey Zwicker, MD
Description To compare the absorption and activity of quercetin or isoquercetin with or without ascorbic acid in healthy adults. Oral chews containing quercetin (500mg) or isoquercetin(500 mg total) with or without ascorbic acid will be given. Pharmacokinetic parameters (AUC, Cmax, Tmax, elimination half-life) will be determined over 24 hours (8 time points). Pharmacodynamic inhibition of protein disulfide isomerase activity will also be assessed. In addition to healthy subjects, a cohort of 10 individuals with antiphospholipid antibodies will participate. These participants will receive isoquercetin 1000 mg and have pharmacodynamics studies performed at time 0 and 4 hours. All study drugs will be provided by Quercegen Pharma.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Beth Israel Deaconess Medical Center.